收费全文 | 402356篇 |
免费 | 27153篇 |
国内免费 | 4675篇 |
耳鼻咽喉 | 5376篇 |
儿科学 | 8530篇 |
妇产科学 | 10376篇 |
基础医学 | 55622篇 |
口腔科学 | 12244篇 |
临床医学 | 32917篇 |
内科学 | 81489篇 |
皮肤病学 | 8764篇 |
神经病学 | 28270篇 |
特种医学 | 15085篇 |
外国民族医学 | 94篇 |
外科学 | 63391篇 |
综合类 | 14540篇 |
一般理论 | 67篇 |
预防医学 | 18899篇 |
眼科学 | 10037篇 |
药学 | 33740篇 |
14篇 | |
中国医学 | 3714篇 |
肿瘤学 | 31015篇 |
2021年 | 3110篇 |
2020年 | 2524篇 |
2019年 | 3430篇 |
2018年 | 5090篇 |
2017年 | 4180篇 |
2016年 | 4221篇 |
2015年 | 5119篇 |
2014年 | 7182篇 |
2013年 | 8714篇 |
2012年 | 11830篇 |
2011年 | 12355篇 |
2010年 | 7601篇 |
2009年 | 6928篇 |
2008年 | 10853篇 |
2007年 | 11767篇 |
2006年 | 11636篇 |
2005年 | 10684篇 |
2004年 | 9849篇 |
2003年 | 9607篇 |
2002年 | 9150篇 |
2001年 | 29012篇 |
2000年 | 29447篇 |
1999年 | 24276篇 |
1998年 | 5416篇 |
1997年 | 4566篇 |
1996年 | 3995篇 |
1995年 | 3759篇 |
1994年 | 3321篇 |
1993年 | 3016篇 |
1992年 | 16215篇 |
1991年 | 14984篇 |
1990年 | 14276篇 |
1989年 | 14071篇 |
1988年 | 12678篇 |
1987年 | 12158篇 |
1986年 | 11175篇 |
1985年 | 10371篇 |
1984年 | 6940篇 |
1983年 | 5615篇 |
1982年 | 2724篇 |
1979年 | 5513篇 |
1978年 | 3366篇 |
1977年 | 2970篇 |
1975年 | 2643篇 |
1974年 | 3076篇 |
1973年 | 2872篇 |
1972年 | 2830篇 |
1971年 | 2765篇 |
1970年 | 2509篇 |
1969年 | 2544篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献